Expression of the ubiquitin ligase subunit cyclin kinase subunit 1 and its relationship to S-phase kinase protein 2 and p27Kip1 in prostate cancer

被引:23
作者
Shapira, Ma'anit
Ben-Izhak, Ofer
Slotky, Merav
Goldin, Oleg
Lahav-Baratz, Shirly
Hershko, Dan D. [1 ]
机构
[1] Rambam Med Ctr, Dept Surg A, IL-31096 Haifa, Israel
[2] Rambam Med Ctr, Dept Pathol, IL-31096 Haifa, Israel
[3] Rambam Med Ctr, Dept Urol, IL-31096 Haifa, Israel
[4] Rambam Med Ctr, Vasc & Tumor Biol Res Ctr, IL-31096 Haifa, Israel
[5] Technion Israel Inst Technol, Haifa, Israel
关键词
prostate; prostatic neoplasms; ubiquitin; cyclin-dependent kinases; CDKN1B protein; human; PROTEASOME-DEPENDENT DEGRADATION; HUMAN BREAST-CANCER; INHIBITOR P27; COLORECTAL CARCINOMAS; SKP2; CKS1;
D O I
10.1016/j.juro.2006.07.051
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Loss of the cell cycle inhibitory protein p27(Kip1) in cancer is associated with tumor aggressiveness and poor prognosis in the prostate. The decrease in p27(Kip1) results from increased proteasome dependent degradation, which is mediated by its specific ubiquitin ligase subunits S-phase kinase protein 2 and cyclin dependent kinase subunit 1. S-phase kinase protein 2 was found to be over expressed in aggressive prostate cancers but to our knowledge the role of cyclin dependent kinase subunit 1 in these cancers is unknown. Materials and Methods: The expression of cyclin dependent kinase subunit 1, S-phase kinase protein 2 and p27(Kip1) was examined by immunohistochemistry in tissue sections from 45 patients with prostate cancer. The expression of cyclin dependent kinase subunit 1 was compared to that of S-phase kinase protein 2 and p27(Kip1), and patient clinical and histological characteristics. Results: Cyclin dependent kinase subunit 1 expression was strongly associated with S-phase kinase protein 2 expression (r = 0.666, p = 0.001) and inversely with p27(Kip1) expression (r = -0.737, p < 0.001). Cyclin dependent kinase subunit 1 over expression was associated with loss of tumor differentiation (r = 0.631, p = 0.001), high serum prostate specific antigen (r 0.627, P < 0.001) and metastatic disease (p < 0.001). Conclusions: These results suggest that cyclin dependent kinase subunit 1 is involved in p27(Kip1) down-regulation and it may have an important causative role in the development of aggressive tumor behavior in prostate cancer.
引用
收藏
页码:2285 / 2289
页数:5
相关论文
共 21 条
  • [1] Control of the SCFSkp2-Cks1 ubiquitin ligase by the APC/CCdh1 ubiquitin ligase
    Bashir, T
    Dorrello, NV
    Amador, V
    Guardavaccaro, D
    Pagano, M
    [J]. NATURE, 2004, 428 (6979) : 190 - 193
  • [2] Inverse relationship between Skp2 ubiquitin ligase and the cyclin dependent kinase inhibitor p27Kip1 in prostate cancer
    Ben-Izhak, O
    Lahav-Baratz, S
    Meretyk, S
    Ben-Eliezer, S
    Sabo, E
    Dirnfeld, M
    Cohen, S
    Ciechanover, A
    [J]. JOURNAL OF UROLOGY, 2003, 170 (01) : 241 - 245
  • [3] SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27
    Carrano, AC
    Eytan, E
    Hershko, A
    Pagano, M
    [J]. NATURE CELL BIOLOGY, 1999, 1 (04) : 193 - 199
  • [4] Overexpression of Skp2 in carcinoma of the cervix does not correlate inversely with p27 expression
    Dowen, SE
    Scott, A
    Mukherjee, G
    Stanley, MA
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2003, 105 (03) : 326 - 330
  • [5] The cell-cycle regulatory protein Cks1 is required for SCFSkp2-mediated ubiquitinylation of p27
    Ganoth, D
    Bornstein, G
    Ko, TK
    Larsen, B
    Tyers, M
    Pagano, M
    Hershko, A
    [J]. NATURE CELL BIOLOGY, 2001, 3 (03) : 321 - 324
  • [6] The ubiquitin system
    Hershko, A
    Ciechanover, A
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 1998, 67 : 425 - 479
  • [7] Hershko D, 2001, CANCER, V91, P1745, DOI 10.1002/1097-0142(20010501)91:9<1745::AID-CNCR1193>3.0.CO
  • [8] 2-H
  • [9] Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas
    Loda, M
    Cukor, B
    Tam, SW
    Lavin, P
    Fiorentino, M
    Draetta, GF
    Jessup, JM
    Pagano, M
    [J]. NATURE MEDICINE, 1997, 3 (02) : 231 - 234
  • [10] Masuda T, 2003, CLIN CANCER RES, V9, P5693